Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: Levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy

被引:22
|
作者
Carr, J. M.
Cheney, K. M.
Coolen, C.
Davis, A.
Shaw, D.
Ferguson, W.
Chang, G.
Higgins, G.
Burrell, C.
Li, P.
机构
[1] Inst Med & Vet Sci, Infect Dis Lab, Adelaide, SA 5000, Australia
[2] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia
[3] Royal Adelaide Hosp, Infect Dis Unit, Adelaide, SA 5000, Australia
关键词
D O I
10.1128/JCM.01926-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have adapted our established Alu PCR assay for proviral DNA and PCR for total cellular DNA to a real-time PCR format and applied these to human immunodeficiency virus (HIV)-positive specimens collected for routine determination of the plasma viral load (pVL). In a cohort of five patients, measurements of integrated viral load (iVL) and cell-associated viral load (cVL) in CD4' cells isolated by a single positive selection step were not indicative of HIV DNA levels in the circulation, and further analysis was performed on peripheral blood mononuclear cells (PBMC). In a cohort of 46 samples total cVL was quantitated in most samples, but iVL could be quantitated in only 47.8%, since in 26% iVL was undetectable and in 21.7% the results were invalid due to high levels of unintegrated HIV DNA. There was no correlation of cVL or WIL with pVL, CD4 count, or duration of successful antiretroviral treatment. Out of 26 patients with undetectable pVL, 4 patients failed therapy within the subsequent 12 months and had higher than average iVL, but this was not the case for cVL. Among nine patients with long-term undetectable pVL, no consistent decline in cVL or iVL was seen with time, and changes in cVL and iVL within a patient could be concordant or discordant. These results show that cVL and iVL can be coordinately measured in PBMC from clinical samples but do not correlate with pVL, CD4 counts, or length of suppressive antiretroviral therapy. Interestingly, a high iVL (but not a high cVL) in patients with undetectable pVL was associated with subsequent treatment failure.
引用
收藏
页码:1288 / 1297
页数:10
相关论文
共 28 条
  • [21] A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans
    Mwau, M
    Cebere, I
    Sutton, J
    Chikoti, P
    Winstone, N
    Wee, EGT
    Beattie, T
    Chen, YH
    Dorrell, L
    McShane, H
    Schmidt, C
    Brooks, M
    Patel, S
    Roberts, J
    Conlon, C
    Rowland-Jones, SL
    Bwayo, JJ
    McMichael, AJ
    Hanke, T
    JOURNAL OF GENERAL VIROLOGY, 2004, 85 : 911 - 919
  • [22] Sensitivity of the multispot HIV-1/HIV-2 rapid test using samples from human immunodeficiency virus type 1-positive individuals with various levels of exposure to highly active antiretroviral therapy
    O'Connell, Robert J.
    Agan, Brian K.
    Anderson, Stephanie A.
    Malia, Jennifer A.
    Michael, Nelson L.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (05) : 1831 - 1833
  • [23] CLINICAL-EVALUATION OF AMPLICOR HIV-1 TEST FOR DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROVIRAL DNA IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS
    KHADIR, A
    COUTLEE, F
    SAINTANTOINE, P
    OLIVIER, C
    VOYER, H
    KESSOUSELBAZ, A
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 9 (03): : 257 - 263
  • [24] MATURE REVERSE-TRANSCRIPTASE (P66/P51) IS RESPONSIBLE FOR LOW-LEVELS OF VIRAL-DNA FOUND IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)
    ARTS, EJ
    MAK, J
    KLEIMAN, L
    WAINBERG, MA
    LEUKEMIA, 1994, 8 : S175 - S178
  • [25] Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients
    Hua, Stephane
    Vigano, Selena
    Tse, Samantha
    Ouyang Zhengyu
    Harrington, Sean
    Negron, Jordi
    Garcia-Broncano, Pilar
    Marchetti, Giulia
    Genebat, Miguel
    Leal, Manuel
    Resino, Salvador
    Ruiz-Mateos, Ezequiel
    Lichterfeld, Mathias
    Yu, Xu G.
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (12) : 1910 - 1917
  • [26] HIGH-LEVELS OF ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) MEMORY CYTOTOXIC T-LYMPHOCYTE ACTIVITY AND LOW VIRAL LOAD ARE ASSOCIATED WITH LACK OF DISEASE IN HIV-1-INFECTED LONG-TERM NONPROGRESSORS
    RINALDO, C
    HUANG, XL
    FAN, Z
    DING, M
    BELTZ, L
    LOGAR, A
    PANICALI, D
    MAZZARA, G
    LIEBMANN, J
    COTTRILI, M
    GUPTA, P
    JOURNAL OF VIROLOGY, 1995, 69 (09) : 5838 - 5842
  • [27] Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
    Cebere, I
    Dorrell, L
    McShane, H
    Simmons, A
    McCormack, S
    Schmidt, C
    Smith, C
    Brooks, M
    Roberts, JE
    Darwin, SC
    Fast, PE
    Conlon, C
    Rowland-Jones, S
    McMichael, AJ
    Hanke, T
    VACCINE, 2006, 24 (04) : 417 - 425
  • [28] Endogenous production of beta-chemokines by CD4(+), but not CD8(+) T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro
    Saha, K
    Bentsman, G
    Chess, L
    Volsky, DJ
    JOURNAL OF VIROLOGY, 1998, 72 (01) : 876 - 881